Real-World Experience with 177 Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval
Journal of Nuclear Medicine · 2024-05 · 65 (5) · 735-739
DOI: 10.2967/jnumed.123.266842 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 14.03.2024. Verfasst von Abuzar Moradi Tuchayi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California. Hauptthemen laut MEDLINE: Lutetium, Heterocyclic Compounds, 1-Ring, Dipeptides, United States Food and Drug Administration. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
We report our initial real-world experience with 177Lu-PSMA-617 radioligand therapy.
Methods
We performed a retrospective review of patients treated with 177Lu-PSMA-617. Pretreatment PSMA PET, laboratory findings, overall survival, a fall in prostate-specific antigen by 50% (PSA50), and toxicities were evaluated.
Results
Ninety-nine patients were included. Sixty patients achieved a PSA50. Seven of 18 (39%) patients who did not meet the TheraP PSMA imaging criteria achieved a PSA50. Nineteen of 31 (61%) patients who did not meet the VISION laboratory criteria achieved a PSA50. Sixty-three patients had a delay or stoppage in therapy, which was due to a good response in 19 patients and progressive disease in 14 patients. Of 10 patients with a good response who restarted treatment, 9 subsequently achieved a PSA50 on retreatment. The most common toxicities were anemia (33%) and thrombocytopenia (21%).
Conclusion
At our center, patients who did not meet the TheraP PSMA imaging criteria or the VISION laboratory criteria benefited from 177Lu-PSMA-617 radioligand therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California.
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California; and.
- Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; thomas.hope@ucsf.edu.
Förderung
- NCI NIH HHS
Zitieren
APA
Moradi Tuchayi, A., Yadav, S., Jiang, F., Kim, S. T., Saelee, R. K., Morley, A., Juarez, R., Lawhn-Heath, C., Wang, Y., de Kouchkovsky, I., & Hope, T. A. (2024). Real-World Experience with 177 Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval. Journal of Nuclear Medicine, 65(5), 735-739. https://doi.org/10.2967/jnumed.123.266842
Vancouver
Moradi Tuchayi A, Yadav S, Jiang F, Kim ST, Saelee RK, Morley A, et al. Real-World Experience with 177 Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval. Journal of Nuclear Medicine. 2024;65(5):735-739. doi:10.2967/jnumed.123.266842
BibTeX
@article{MoradiTuchayi2024,
author = {Moradi Tuchayi, Abuzar and Yadav, Surekha and Jiang, Fei and Kim, Sarasa T and Saelee, Rachelle K and Morley, Amanda and Juarez, Roxanna and Lawhn-Heath, Courtney and Wang, Yingbing and de Kouchkovsky, Ivan and Hope, Thomas A},
title = {Real-World Experience with 177 Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval},
journal = {Journal of Nuclear Medicine},
year = {2024},
volume = {65},
number = {5},
pages = {735--739},
doi = {10.2967/jnumed.123.266842}
}
EUVIMED